Company intelligence / Profile preview

HiberCell

New York City, New York, United Stateshibercell.com ↗

Ownership: Private
Development stage: Phase 1

Overview

HiberCell has initiated Phase I clinical trials for its lead candidate HC‑5404‑FU targeting PERK in advanced solid tumors. Another candidate, HC‑7366 targeting GCN2/EIF2AK4, was previously in clinical development but appears to be discontinued. The company’s approach centers on overcoming treatment resistance and preventing cancer relapse/metastasis by disrupting stress-adaptive pathways and tumor dormancy. Some pipeline assets have been discontinued or are at the preclinical stage. No late-stage or commercialized products as of May 2025.

Therapeutic areas: OncologyEndocrinology
Modalities: Small moleculesMonoclonal antibodiesChemical drugsPolymer-based therapeutics
Industry: Biotech

Drug pipeline

8 assets

odetiglucan

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on HiberCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HiberCell.

Explore the full profile